The effect of antivirals on COVID-19: a systematic review

References

• Worldometer. COVID-19 CORONAVIRUS PANDEMIC [Internet]. [ cited 2020 Sep 3]. Available from: https://www.worldometers.info/coronavirus/
   Google Scholar
• Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol [Internet]. 2020. DOI: 10.1002/jmv.25964.
   Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA [Internet]. 2020 Apr 7;323(13):1239. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130.
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Han Y, Feng Z, Sun L, et al. A comparative‐descriptive analysis of clinical characteristics in 2019‐coronavirus‐infected children and adults. J Med Virol [Internet]. 2020;92:1596–1602.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020. 579(7798):270–273.
   Web of Science ®Google Scholar
• Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. [Internet]
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax [Internet]. 2004;59:252–256.
   PubMed Web of Science ®Google Scholar
• Chen F, Chan K, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol [Internet]. 2004. DOI: 10.1016/S1386-6532(04)00055-1.
   Web of Science ®Google Scholar
• Wu C-Y, Jan J-T, Ma S-H, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci [Internet]. 2004;101(27):10012–10017.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med [Internet]. 2020 7 382(19):1787–1799. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona virus disease 2019: A retrospective cohort study. J Infect [Internet]. 2020;81:e1–e5.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2). DOI:10.1128/mBio.00221-18
   PubMed Web of Science ®Google Scholar
• Nitulescu GM, Paunescu HO, Moschos SA, et al. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: mechanistic insights into current COVID-19 therapies. Int J Mol Med. 2020;46:467–488.
   PubMed Web of Science ®Google Scholar
• Alexander SP, Armstrong J, Davenport AP, et al. A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR review “XXX”. British J Pharmacol. 2020. DOI: 10.1111/bph.15094
   Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020 Apr 10;295(15):4773–4779.
   Web of Science ®Google Scholar
• Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020 Mar 25:117592.
   Web of Science ®Google Scholar
• Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv [Internet]. 2020 Jan 1.
   Google Scholar
• Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26(7):917–921. [Internet]
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med [Internet]. 2020;382(24):2327–2336.
   PubMed Web of Science ®Google Scholar
• Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA [Internet]. 2020;323:1488.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. [Internet].
   PubMed Web of Science ®Google Scholar
• Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect [Internet]. 2020;81(1):e21–e23.
   PubMed Web of Science ®Google Scholar
• Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet [Internet]. 2020;395:1695–1704.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64–68. [Internet]
   PubMed Web of Science ®Google Scholar
• Xiong Y, Song S, Ye G, et al. Family cluster of three recovered cases of pneumonia due to severe acute respiratory syndrome coronavirus 2 infection. BMJ Case Rep. 2004;13(5):e235302. [Internet]
   Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering [Internet]. 2020. DOI: 10.1016/j.eng.2020.03.007.
   Web of Science ®Google Scholar
• Colaneri M, Sacchi P, Zuccaro V, et al. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill [Internet]. 2020;25(16). DOI: 10.2807/1560-7917.ES.2020.25.16.2000460.
   PubMedGoogle Scholar
• Shi X, Lu Y, Li R, et al. Evaluation of antiviral therapies for coronavirus disease 2019 (COVID‐19) pneumonia in Shanghai, China. J Med Virol [Internet]. 2020. DOI: 10.1002/jmv.25893.
   Web of Science ®Google Scholar
• Fernández‐Ruiz M, Andrés A, Loinaz C, et al. COVID‐19 in solid organ transplant recipients: A single‐center case series from Spain. Am J Transplant [Internet]. 2020;20:1849–1858.
   PubMed Web of Science ®Google Scholar
• Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Futur Oncol. 2020;16(20):1425–1432. [Internet].
   PubMed Web of Science ®Google Scholar
• Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J [Internet]. 2020;55(5):2000547.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901.
   PubMed Web of Science ®Google Scholar